Contact this trialFirst, we need to learn more about you.
Radioactive Drug
Lutetium Lu 177 Dotatate for Lung Carcinoid Tumor
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial compares lutetium Lu 177 dotatate to the usual treatment, everolimus, for patients with neuroendocrine tumors that have spread to other parts of the body. Lutetium Lu 177 dotatate may be more effective than everolimus and cause less harm to normal cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.